A Long Term Safety Study of Degarelix in Patients With Prostate Cancer
Status:
Completed
Trial end date:
2011-12-01
Target enrollment:
Participant gender:
Summary
Patients that completed any of the trials; CS27 (NCT00738673), CS28 (NCT00831233), CS30
(NCT00833248) or CS31 (NCT00884273) will be given the opportunity to receive monthly doses of
degarelix until the drug is launched in their country. Safety parameters such as
electrocardiogram (ECG), blood and urine samples and general health state will be studied.
Note: patients completing the CS27 trial did not participate in the CS34 trial.